Zolgensma will still be the first $1B gene therapy

By Anthony Davies

Say what you will about Novartis; it’s always interesting over there by the Rhine. It’s been a rollercoaster of news about Zolgensma lately—from the timing of the data manipulation reporting…to the excellent 3Q earnings…to Japan and the …

We use cookies to help give you the best experience on our website. By continuing you agree to our use of cookies.